Literature DB >> 390300

Hypoparathyroidism.

N A Breslau, C Y Pak.   

Abstract

Recent advances in our understanding of the physiologic actions of PTH and vitamin D have clarified certain aspects of the pathogenesis, classification, and management of hypoparathyroidism. Central to pathogenesis and categorization is the recognition that hypoparathyroidism may result from PTH deficiency, ineffectiveness, or resistance, with a resultant inability to stimulate adenylate cyclase in target tissues. This aberration in adenylate cyclase activity impairs certain physiologic responses such as renal phosphate excretion and renal calcium reabsorption that are required for proper calcium homeostasis. Also critical is the subnormal production of 1 alpha,25-dihydroxycholecalciferol (1,25-DHCC). Although the precise mechanism for the deficiency of 1,25-DHCC remains unclear, one may hypothesize that in hormone-deficient or hormone-ineffective hypoparathyroidism, decreased synthesis results from the absence of the two recognized stimuli for 1 alpha-hydroxylase--bioactive PTH and hypophosphatemia. Provision of either one of these stimuli would then be expected to restore 1,25-DHCC to normal levels, which could explain the calcemic response to PTH in these patients. There is some evidence that the synthesis of 1,25-DHCC may be "primarily" affected in PTH-resistant hypoparathyroidism, and thus may be unresponsive to any of the known stimuli. It remains conceivable, however, that during normocalcemic phases, such patients may improve their renal cyclic AMP and phosphaturic responses to PTH, with associated improvement in 1,25-DHCC synthesis. Certain acquired forms of PTH resistance such as hypomagnesemia and end-stage renal disease may also be associated with defective 1-hydroxylation. Whether occurring primarily or as a secondary process, the subnormal production of 1,25-DHCC may influence calcium and skeletal metabolism directly or by modifying response to PTH. The availability of 1,25-DHCC provides an effective and physiologically meaningful mode of therapy for most cases of hypoparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 390300     DOI: 10.1016/0026-0495(79)90141-0

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  8 in total

1.  Hypocalcemic heart failure in thalassemic patients.

Authors:  M Tsironi; K Korovesis; D Farmakis; S Deftereos; A Aessopos
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

Review 2.  Endocrine control and disturbances of calcium and phosphate metabolism in children.

Authors:  K Kruse
Journal:  Eur J Pediatr       Date:  1987-07       Impact factor: 3.183

3.  Effect of bendrofluazide on calcium reabsorption in hypoparathyroidism.

Authors:  G H Newman; M Wade; D J Hosking
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Pseudohypoparathyroidism and hypocalcemic "myopathy". A case report.

Authors:  H Piechowiak; W Gröbner; H Kremer; D Pongratz; J Schaub
Journal:  Klin Wochenschr       Date:  1981-11-02

5.  Spontaneous hypoparathyroidism: clinical, biochemical and radiological features.

Authors:  A Mithal; P S Menon; A C Ammini; M G Karmarkar; M M Ahuja
Journal:  Indian J Pediatr       Date:  1989 Mar-Apr       Impact factor: 1.967

6.  A case of hypocalcemia-induced dilated cardiomyopathy.

Authors:  Joong Kyung Sung; Jang-Young Kim; Dong-Wook Ryu; Jun-Won Lee; Young-Jin Youn; Byung-Su Yoo; Kyung-Hoon Choe
Journal:  J Cardiovasc Ultrasound       Date:  2010-03-31

7.  Renal handling of calcium in hypoparathyroidism.

Authors:  G H Newman; M Wade; D J Hosking
Journal:  Br Med J (Clin Res Ed)       Date:  1983-09-17

8.  Effects of 1,25 dihydroxyvitamin D3 administration on circadian mineral rhythms in humans.

Authors:  M E Markowitz; J F Rosen; M Mizruchi
Journal:  Calcif Tissue Int       Date:  1985-07       Impact factor: 4.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.